Syncom Formulations (India) Ltd.
Snapshot View

View in App

Prices View details >>

9.18 -0.07 ▼-0.8%

12 August 2022, 04:01:00 PM
Volume: 1,514,945

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.sfil.in
Market Cap 862.92 Cr.
Enterprise Value(EV) 920.33 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 0.21 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 43.60 Trailing Twelve Months Ending 2022-03
Industry PE 32.02 Trailing Twelve Months Ending 2022-03
Book Value / Share 2.57 Trailing Twelve Months Ending 2022-03
Price to Book Value 3.57 Calculated using Price: 9.18
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 94.00 Cr. 940,000,000 Shares
FaceValue 1
Company Profile
Syncom Formulations (India) Ltd was originally incorporated as Syncom Formulations (India) Private Limited in the state of Maharashtra on June 21, 1988 under the Companies Act, 1956. Further the status of company was changed to public limited company and thereby name of company changed to Syncom Formulations (India) Limited and a fresh certificate of change of name obtained on July 9, 1992.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-0.76%
1 Week
+2.00%
1 Month
+15.47%
3 Month
+7.62%
6 Month
-35.80%
1 Year
+26.10%
2 Year
+330.99%
5 Year
+546.48%
10 Year
+477.36%

Ratios View Details >>

9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 6.60 10.19 9.99 9.91 9.56 7.33 8.71 10.24 18.04
Return on Capital Employed (%) 9.98 15.29 15.55 14.72 13.58 9.43 9.37 12.39 20.68
Return on Assets (%) 4.76 6.95 6.82 6.41 5.93 4.90 6.34 7.92 12.02

Balance Sheet View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 88 95 100 109 114 122 133 146 188 222
Non Curr. Liab. 8 7 6 6 8 9 8 7 7 8
Curr. Liab. 29 42 37 66 56 43 36 31 106 78
Minority Int.
Equity & Liab. 124 144 143 181 179 174 176 184 301 308
Non Curr. Assets 63 66 59 89 92 93 95 95 102 168
Curr. Assets 62 78 83 92 87 81 81 89 200 140
Misc. Exp. not W/O
Total Assets 124 144 143 181 179 174 176 184 301 308

Profit Loss View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 115 151 173 184 185 159 187 206 245 220
Other Income 1 1 2 3 3 4 5 5 7 12
Total Income 116 152 175 187 188 163 192 211 252 232
Total Expenditure -104 -135 -155 -167 -168 -147 -175 -189 -207 -200
PBIDT 12 17 20 19 19 16 17 22 45 31
Interest -1 0 0 0 0 0 0 -1 0 -1
Depreciation -3 -3 -3 -3 -3 -4 -4 -4 -4 -4
Taxation -3 -5 -6 -6 -5 -3 -2 -3 -12 -6
Exceptional Items -1 0 0 0 0 0 0
PAT 6 9 10 10 11 9 11 14 29 20
Adjusted EPS 0 0 0 0 0 0 0 0 0 0

Cash Flow View Details >>

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 6 6 7 0 24 17 -2 4 6 -2
Cash Fr. Inv. -5 0 -4 1 -23 -8 -2 2 2 -73
Cash Fr. Finan. -1 -6 -1 1 -2 -2 -2 0 -7 72
Net Change 1 -1 2 2 -1 6 -6 7 1 -3
Cash & Cash Eqvt 5 4 5 7 6 7 1 7 8 5

Shareholding Pattern View Details >>

9 Qtrs 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%)
Promoter 40.48 40.48 40.48 41.18 41.18 44.01 44.01 46.12 50.57
Public 59.52 59.52 59.52 58.82 58.82 55.99 55.99 53.88 49.43
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Sat, 13 Aug 2022
Submission Of The Un-Audited Financial Results Along With Limited Review Report Thereon For The Quarter Ended 30Th June 2022 As Per Regulation 33(3)(D) Of SEBI (LODR) Regulations 2015.
Pursuant to Regulation 33(3)(d) of SEBI (LODR) Regulations 2015 we are pleased to submit the Un-Audited Financial Results along with Limited Review Report thereon for the quarter ended 30th June 2022 in PDF Format which were also approved by the Audit Committee and Board of Directors at their meeting held on Saturday 13th August 2022.
Sat, 13 Aug 2022
Corporate Announcement/Information Pursuant To Regulation 44 Of The SEBI (LODR) Regulations 2015 Regarding Providing Remote-E Voting Facilities For The 34Th Annual General Meeting To Be Held On 19Th September 2022.
We hereby submit the following informations for the investors/ members of the Company:-Sr.No. Heading Particulars1 Name of the Agency providing E-voting platform CDSL2 Name of the Agency providing E-voting facility at AGM and VC/OAVM platform CDSL3 Cut-off date for E-voting entitlement 12.09.20224 Voting Start Date & Time 16.09.2022 at 9:00 A.M. (IST)5 Voting End Date & Time 18.09.2022 at 5:00 P.M. (IST)6 Name of the Scrutinizers CS Anish Gupta Practicing Company Secretary
Sat, 13 Aug 2022
Board Meeting Outcome for Outcome Of 5/2022-23 Board Meeting
Outcome of the 5/2022-23 Meeting of the Board of Directors of the Company held on Saturday 13th August 2022 at 207 Saket Nagar Near Saket Club Indore (M.P.) 452018 at 4:00 P.M. as per Regulation 30 read with Schedule III(A)(IV) of the SEBI(LODR) Regulations 2015.

Technical Scans View Details >>

Fri, 12 Aug 2022
Opening at High Opening at High
High Increase 1 Month High Increase 1 Month
High Decrease 6 Months High Decrease 6 Months
High Increase 2 Years High Increase 2 Years
High Increase 5 Years High Increase 5 Years

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,167.25 913.45 -0.8%
Divi's Laboratories Ltd. 98,918.90 3,726.20 -5.6%
Cipla Ltd. 82,906.37 1,027.35 -1.1%
Dr. Reddy's Laboratories Ltd. 70,920.35 4,260.80 +0.1%
Apollo Hospitals Enterprise Ltd. 62,010.73 4,312.75 -2.6%
Torrent Pharmaceuticals Ltd. 51,917.53 1,534.00 -0.1%
Piramal Enterprises Ltd. 45,855.65 1,921.35 +0.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-06 56.35 913.45 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 33.43 3,726.20 -5.6%
Cipla Ltd. Consolidated 2022-06 33.32 1,027.35 -1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-06 23.69 4,260.80 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-06 70.15 4,312.75 -2.6%
Torrent Pharmaceuticals Ltd. Consolidated 2022-06 64.82 1,534.00 -0.1%
Piramal Enterprises Ltd. Consolidated 2022-06 24.38 1,921.35 +0.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-06 4.37 913.45 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 8.44 3,726.20 -5.6%
Cipla Ltd. Consolidated 2022-06 3.86 1,027.35 -1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-06 3.50 4,260.80 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-06 10.43 4,312.75 -2.6%
Torrent Pharmaceuticals Ltd. Consolidated 2022-06 8.12 1,534.00 -0.1%
Piramal Enterprises Ltd. Consolidated 2022-06 1.28 1,921.35 +0.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.02 913.45 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,726.20 -5.6%
Cipla Ltd. Consolidated 2022-03 0.04 1,027.35 -1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,260.80 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,312.75 -2.6%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,534.00 -0.1%
Piramal Enterprises Ltd. Consolidated 2022-03 1.56 1,921.35 +0.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 913.45 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,726.20 -5.6%
Cipla Ltd. Consolidated 2022-03 13.10 1,027.35 -1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,260.80 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,312.75 -2.6%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,534.00 -0.1%
Piramal Enterprises Ltd. Consolidated 2022-03 3.87 1,921.35 +0.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 913.45 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,726.20 -5.6%
Cipla Ltd. Consolidated 2022-03 13.10 1,027.35 -1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,260.80 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,312.75 -2.6%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,534.00 -0.1%
Piramal Enterprises Ltd. Consolidated 2022-03 3.87 1,921.35 +0.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 913.45 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,726.20 -5.6%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,027.35 -1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,260.80 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,312.75 -2.6%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,534.00 -0.1%
Piramal Enterprises Ltd. Consolidated 2022-03 13,993.30 1,921.35 +0.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 913.45 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,726.20 -5.6%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,027.35 -1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,260.80 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,312.75 -2.6%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,534.00 -0.1%
Piramal Enterprises Ltd. Consolidated 2022-03 1,345.89 1,921.35 +0.8%

FAQ's On Syncom Formulations (India) Ltd.

Can I Buy Syncom Formulations Shares now?
What is the Share Price of Syncom Formulations?
What is the Relative Strength Index (RSI) Value of Syncom Formulations?
What is the Market Capital (MCAP) of Syncom Formulations?
What are the key metrics to analyse Syncom Formulations?
What is the Price Performance of Syncom Formulations?